HER2-therapy resistance is associated with downstream signal activation by compensatory pathways, mutations in the HER2-TK domain, tumor stem cell self-renewal, host immune regulation, and epigenetic effects (D’Amato et al., 2015; Xing et al., 2023). This evidence concerns the gene ERBB2 and neoplasm.